One of two projects recently funded by Alport Syndrome Foundation (USA).
Home » latest news » research » correction of the genetic defect in Alport syndrome using the TALEN approach
Comments are closed.
December 6th, 2022
Eloxx, a pharmaceutical company, is testing a new treatment that they think might help certain people with Alport Syndrome. Alport syndrome is caused by changes (called mutations) in certain genes. Only
read more